References
- Zava TT , ZavaDT. Validation of dried blood spot sample modifications to two commercially available COVID-19 IgG antibody immunoassays. Bioanalysis13(1), 13–28 (2020).
- Marchand A , RoullandI, SemenceF, EricssonM. Adaptation of Elecsys® anti-severe acute respiratory syndrome coronavirus-2 immunoassay to dried blood spots: proof of concept. Bioanalysis13(3), 161–167 (2021).
- Bioanalysis Special Focus Issue. COVID-19: bioanalytical considerations, contributions and lessons – part 1. https://www.tandfonline.com/toc/bio/13/15
- Bioanalysis Special Focus Issue. COVID-19: bioanalytical considerations, contributions and lessons – part 2. https://www.tandfonline.com/toc/bio/13/22
- Manohar SM , ShahP, NairA. Flow cytometry: principles, applications and recent advances. Bioanalysis13(3), 181–198 (2021).
- Cohen S , ChungS. In vitro immunogenicity prediction: bridging between innate and adaptive immunity. Bioanalysis13(13), 1071–1081 (2021).
- A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies. Bioanalysis13(14), 1135–1144 (2021).
- Hashii N , TousakaY, AraiKet al. Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC–MS. Bioanalysis13(4), 265–276 (2021).
- Gorovits B . Complexity and diversity of bioanalytical support for gene therapy modalities. Bioanalysis13(2), 65–68 (2021).
- Wickremsinhe ER , JamesCA. Bioanalysis and the oncology revolution. Bioanalysis13(5), 291–294 (2021).
- Neubert H , AlleySC, LeeAet al. 2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (Part 1 – Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in Small Molecules, Peptides and Oligos). Bioanalysis13(4), 203–238 (2021).
- Spitz S , ZhangY, FischerSet al. 2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A – Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B – Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis13(5), 295–361 (2021).
- Corsaro B , YangT-Y, MurphyRet al. 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 – Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis13(6), 415–463 (2021).
- Laurén A , GoodmanJ, BlaesJet al. A strategic approach to nonclinical immunogenicity assessment: a recommendation from the European Bioanalysis Forum. Bioanalysis13(7), 537–549 (2021).
- Bower J , ZimmerJ, McCownSet al. Recommendations for the content and management of Certificates of Analysis for reference standards from the GCC for bioanalysis. Bioanalysis13(8), 609–619 (2021).
- Bioanalysis Special Focus Issue. Critical Reagents: Advanced Applications. https://www.tandfonline.com/toc/bio/13/10
- Bioanalysis Special Focus Issue. Flow Cytometry. https://www.tandfonline.com/toc/bio/13/21
- ScholarOne Manuscripts™. Bioanalysis. https://mc04.manuscriptcentral.com/fs-bio
- Bioanalysis LinkedIn Group . http://www.linkedin.com/groups/2819540
- Bioanalysis Zone . http://www.bioanalysis-zone.com